Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Saturday.
Separately, Maxim Group lifted their price target on shares of Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 31st.
Brainstorm Cell Therapeutics Stock Performance
BCLI opened at $2.85 on Friday. The stock has a market capitalization of $112.32 million, a PE ratio of -4.32 and a beta of -0.38. Brainstorm Cell Therapeutics has a one year low of $1.09 and a one year high of $4.70. The business’s 50 day moving average price is $2.54 and its 200 day moving average price is $2.15.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in BCLI. Tower Research Capital LLC TRC raised its holdings in shares of Brainstorm Cell Therapeutics by 739.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 7,806 shares during the period. Jane Street Group LLC purchased a new stake in Brainstorm Cell Therapeutics during the second quarter worth about $33,000. Raymond James Financial Services Advisors Inc. purchased a new stake in Brainstorm Cell Therapeutics during the first quarter worth about $37,000. XTX Topco Ltd acquired a new stake in shares of Brainstorm Cell Therapeutics during the first quarter worth about $40,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the first quarter valued at approximately $42,000. 10.61% of the stock is currently owned by institutional investors and hedge funds.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics, Inc is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer’s disease, and other neurodegenerative diseases.
- Get a free copy of the StockNews.com research report on Brainstorm Cell Therapeutics (BCLI)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.